Accès ouvert · CC BY

Evaluation of the biodistribution of [99mTc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [68Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy

Article scientifique 2026 Sciences de la santé Anglais

Résumé

Abstract Background PSMA-PET/CT became an important means for prostate cancer management. The high-resolution and signal-to-noise ratio of PET is mandatory in primary staging or biochemical relapse that often present with tiny lesions. PSMA-PET is also used to select patients for PSMA-targeted radioligand-therapy, but scanner availability increasingly becomes a bottleneck. The resolution of PSMA-SPECT/CT might be sufficient to tailor PSMA positive vs. negative disease and would help overcome supply limitations. This prospective, monocentric study evaluates the biodistribution and tumor uptake of [ 99m Tc]Tc-PSMA-GCK01 in an intra-individual head-to-head comparison with [ 68 Ga]PSMA-11 to assess its suitability for phenotyping prior to RLT. Results A cohort of ten patients (median age, 68 y; range, 56–85 y) with advanced-stage, metastatic prostate cancer underwent both unenhanced [ 68 Ga]PSMA-11 PET/CT and [ 99m Tc]Tc-PSMA-GCK01 SPECT/CT scans with a mean time interval of 6 days (± 1). The tracer uptake in malignant lesions and normal organs was assessed visually and semi-quantitatively using spherical VOIs by two nuclear medicine physicians in consensus. Compared to [ 99m Tc]Tc-PSMA-GCK01, [ 68 Ga]PSMA-11 displayed a trend toward higher uptake in normal organs. Renal tracer uptake was significantly higher with [ 68 Ga]PSMA-11 than with [ 99m Tc]Tc-PSMA-GCK01. In the salivary glands and liver, there was no statistically significant difference in uptake between the two tracers, although [ 99m Tc]Tc-PSMA-GCK01 displayed a trend toward lower uptake. Conclusion Our study demonstrates intraindividual comparability of [ 99m Tc]Tc-PSMA-GCK01 and [ 68 Ga]PSMA-11 with respect to normal-organ distribution including typical reference organs such as the liver or salivary glands. If only lesions > 2 cm are considered, [ 99m Tc]Tc-PSMA-GCK01 PSMA-SPECT is a viable, cost-effective alternative to [ 68 Ga]PSMA-11 to stratify patients toward or against PSMA-RLT.

Citer ce document

Novruzov, E., Mamlins, E., Kabunda, J., Cardinale, J., Qebetu, M., Kratochwil, C., Feisthauer, A., Martlbauer, S., Kaoma, C. A., Sibiya, S. M., Bruin, T. D., Mdanda, S., Shungube, M., Davis, C., Smith, L., Mzizi, Y., Mokoala, K., Ndlovu, H., Ramonaheng, K., Giesel, F. L., & Sathekge, M. (2026). Evaluation of the biodistribution of [99mTc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [68Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy. EJNMMI Research. https://doi.org/10.1186/s13550-026-01501-0

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 02/10/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 18

Téléchargements (hors robots) : 0

Méthode de comptage